Highlights
- The global Longevity Tech ecosystem comprises 312 companies, of which 103 are funded, with 6 IPOs and 3 acquisitions to date. Genomics is the largest funded segment at $1.4B, followed by Geriatrics at $880M and Ophthalmology at $787M.
- Funding reached $729M across 13 rounds in 2026 YTD, higher than any full year since 2022. Three rounds — NewLimit's $435M Series C, Tenpoint Therapeutics' $85M Series B, and Life Biosciences' $80M Series D — account for approximately 82% of the year's total.
- Annual funding moved from $448M in 2022 to $427M in 2023, $297M in 2024, and $455M in 2025. Round counts over the same period stayed within a narrow band of 17 to 21, before falling to 13 in 2026 YTD.
- The United States leads all geographies with $3.3B raised across 98 rounds, close to 90% of global funding. NewLimit ($682M) and Human Longevity ($377M) together account for approximately 32% of the US total.
- Switzerland, the UK, France, and Australia round out the top five funded geographies, at $94M, $67M, $63M, and $56M respectively. Rejuveron Life Sciences accounts for 81% of Switzerland's total and PulseSight for 86% of France's, while the UK's total is spread across 23 rounds, the second-highest round count globally.
Overview of the Longevity Tech Report
Tracxn, a global market intelligence platform tracking private company and investor data, released its latest Longevity Tech Report, examining funding activity, sector dynamics and geographical investment trends across one of healthcare's fastest-growing innovation categories. Genomics is the single largest funded category at $1.4B, followed by Geriatrics, Ophthalmology, Life Sciences Tech, and Healthcare IT. The United States leads on both funded company count and capital raised, with NewLimit and Human Longevity accounting for close to a third of the country's funding, while the UK shows funding spread across a broader base of smaller rounds. Six companies have listed publicly and three have been acquired.
The US leads global Longevity Tech funding, followed by Switzerland, UK The United States remains the centre of global Longevity Tech investment, raising $3.3B across 98 funding rounds and accounting for nearly 90% of total funding in the ecosystem. Switzerland follows with $94M across seven rounds, with Rejuveron Life Sciences contributing approximately 81% of the country's total funding, underscoring the concentration of investment within its Longevity Tech ecosystem. The UK has attracted $67M across 23 rounds, the second-highest round count of any geography, driven by sustained early-stage activity across Shift Bioscience ($29M) and GlycanAge ($13M). France and Australia remain relatively concentrated funding hubs. France has raised $63M across 11 rounds, with PulseSight accounting for approximately 86% of the country's funding, while Australia's $56M has been raised across just two rounds, highlighting the concentration of capital among a small number of companies.
Longevity Tech Funding Rises from $455M in 2025 to $729M in 2026 YTD Across 13 Rounds Funding across the ecosystem moved from approximately $448M in 2022 to $455M in 2025, with $729M already raised across 13 rounds in 2026 YTD. The increase in 2026 was driven largely by three landmark rounds: NewLimit's $435M Series C, Tenpoint Therapeutics' $85M Series B, and Life Biosciences' $80M Series D. Together, these three rounds accounted for approximately 82% of 2026's funding to date, concentrated in capital-intensive segments such as epigenetic reprogramming, ophthalmic therapeutics, and age-related disease research. Round counts held between 17 and 21 through 2022–2025 before falling to 13 in 2026 YTD.
Genomics and Geriatrics Lead Sector-Level Funding Genomics is the top-funded sector at $1.4B across 27 rounds, led by NewLimit ($682M) and Human Longevity ($377M). Geriatrics follows at $880M across 32 rounds, with funding concentrated among Life Biosciences ($216M), Cambrian BioPharma ($216M), and Retro ($180M), which together account for nearly 70% of the sector's total. Ophthalmology ($787M across 43 rounds), Life Sciences Tech ($324M across 10 rounds), and Healthcare IT ($163M across 15 rounds) round out the top five funded sectors. Tenpoint Therapeutics ($155M) is the top-funded company in Ophthalmology, the sector with the highest round count in the ecosystem.
